NR0B2 and metastatic neoplasm: Although the combination of PD-1 blockade with SHP-1 inhibition presented no additional reduction in primary tumor growth compared to SHP-1 inhibition alone, the combinatorial treatment significantly (P < 0.01) reduced metastatic disease (Fig. 6b).